CSL Limited - Premium Company Report Australia

30-06-2012, 22 pages

CSL Limited is a Public Company that is ranked number 68 out of the top 2000 companies in Australia. The company generates the majority of its income from the Pharmaceutical Product Manufacturing in Australia industry.

In 2012 the company generated total revenue of $4,623,700,000 including sales and other revenue. In 2012 CSL Limited had 10515 employees in Australia including employees from all subsidiaries under the company's control.

The Chief Executive of CSL Limited is Dr Brian McNamee whose official title is Chief Executive Officer & Managing Director. The Chairman of CSL Limited is Prof John Shine whose official title is Non-Executive Chairman.

CSL Limited develops and manufactures vaccines and plasma protein biotherapies. The company operates through the following business units:

CSL Behring - This unit is solely involved in the development, production and distribution of plasma products that is used to manufacture coagulation therapies to treat haemophilia, critical care products for shock in trauma treatment, immunoglobulins for infection treatment and autoimmune diseases. Plasma is also used in wound treatment therapies to minimise blood loss. Human blood plasma is sourced from its collection centres and commercial purchases through CSL Plasma.

CSL Biotherapies - This unit produces and distributes biological products including prescription medicines, vaccines, anti-venoms, in-licensed pharmaceuticals and immunohaematology products and plasma-derived products to treat and prevent serious human medical conditions. Also, it produces and distributes vitro diagnostic products.

Research & Development - This unit focuses on new product development, life-cycle management and safety of the product portfolio.

IBISWorld Premium Company Reports

The IBISWorld Company Premium Report offers a wealth of information on the top 550 companies. The detailed information and analysis in the Premium Report help you become better informed on all company activities. IBISWorld Company Premium Reports include: